{"id":172484,"date":"2025-11-18T07:33:32","date_gmt":"2025-11-18T12:33:32","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172484"},"modified":"2025-11-18T07:33:32","modified_gmt":"2025-11-18T12:33:32","slug":"unichem-labs-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/unichem-labs-q2-fy26-earnings-results\/","title":{"rendered":"Unichem Labs Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q2-fy26-earnings-results\" class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0 md:text-lg [hr+&amp;]:mt-4\">Q2 FY26 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Revenue from Operations: \u20b9578.96 crore, up 9.9% QoQ from \u20b9526.60 crore in Q1 FY26, and up 14.1% YoY from \u20b9507.36 crore in Q2 FY25.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">EBITDA (approx.): \u20b987.15 crore, EBITDA margin at 15.05%, up from 12.65% in Q2 FY25.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Operating Profit (PBDIT, excl. Other Income): \u20b966.18 crore, margin 11.43% vs 10.94% YoY.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Profit Before Tax (PBT): Loss of \u20b910.82 crore, down from profit of \u20b927.13 crore in Q2 FY25.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Profit After Tax (PAT): Loss of \u20b911.89 crore, compared to a profit of \u20b924.63 crore in Q2 FY25 and a loss of \u20b910.47 crore in Q1 FY26.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">PAT margin: -2.05%, sharply lower from +4.85% YoY, indicating profitability pressures.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">EPS: Negative \u20b91.69, compared to positive \u20b93.48 in Q2 FY25.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Key items: Loss impacted by exceptional expenses (notably\u2014a \u20b958.26 crore provision related to the settlement of a European Commission fine).\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Employee costs: \u20b9100.13 crore, marginally lower YoY.\u200b<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3 id=\"management-commentary--strategic-decisions\" class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0 md:text-lg [hr+&amp;]:mt-4\">Management Commentary &amp; Strategic Decisions<\/h3>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Management noted that <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/51e4e766-e94c-4dcd-835d-fc67225b7e08.pdf\" target=\"_blank\" rel=\"noopener\">robust revenue growth was offset by higher costs<\/a>, elevated interest expense, and the one-time exceptional item related to a legacy compliance settlement.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Focus areas include stabilizing operations, optimizing the portfolio, and disciplined cost management in the face of market and regulatory headwinds.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The company remains debt-light with a low net debt\/equity of 0.14.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Stable promoter holding and history of 12.8% 5-year sales CAGR reinforce underlying business stability.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Ongoing investments in product pipeline and global reach are expected to lay the foundation for medium-term margin improvement and a return to profitability once exceptional costs normalize.\u200b<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-172485\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results-839x1024.png\" alt=\"Unichem Labs Q2 FY26 Earnings Results\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q1-fy26-earnings-results\" class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0 md:text-lg [hr+&amp;]:mt-4\">Q1 FY26 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Revenue from Operations: \u20b9526.60 crore, up 3.6% YoY from \u20b9508.55 crore in Q1 FY25, but down 10.3% QoQ.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">EBITDA (approx.): \u20b988.79 crore, margin 16.87% vs 13.94% YoY.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Profit Before Tax (PBT): Loss of \u20b99.02 crore, improved from a \u20b9125.87 crore loss in Q4 FY25, but worse than a profit of \u20b915 crore YoY.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Profit After Tax (PAT): Loss of \u20b910.47 crore, compared to a profit of \u20b92 crore in Q1 FY25.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">EPS: Negative \u20b91.49 (from positive \u20b90.28 in Q1 FY25).\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Margins improved sequentially despite the loss, reflecting early positive impact of efficiency measures.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Management noted significant improvement in sequential loss reduction and remains committed to cost controls and operational turnaround.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>To view the company\u2019s previous earnings and latest concall transcripts,\u00a0<a href=\"https:\/\/44.250.171.167\/symbol\/unichemlab\/\">click here<\/a>\u00a0 to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. &nbsp; Q2 FY26 Earnings Results Revenue from Operations: \u20b9578.96 crore, up 9.9% QoQ from \u20b9526.60 crore in Q1 FY26, and up 14.1% YoY from \u20b9507.36 crore in Q2 FY25.\u200b EBITDA (approx.): \u20b987.15 crore, EBITDA margin at 15.05%, up from 12.65% [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":172485,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[1115],"class_list":["post-172484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Unichem-Labs-Q2-FY26-Earnings-Results.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170341,"url":"https:\/\/alphastreet.com\/india\/unichem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":172484,"position":0},"title":"Unichem Laboratories Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 19, 2025","format":false,"excerpt":"Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. The company operates 3 formulation facilities at Goa, Baddi, and Ghaziabad, and 3 API facilities at Roha, Pithampur, and Kolhapur. The company has initiated backward integration and upscaling for 6-8 major captive APIs. At the\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Unichem Laboratories Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172440,"url":"https:\/\/alphastreet.com\/india\/torrent-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172484,"position":1},"title":"Torrent Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 17, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b93,302 crore, up 14% YoY from \u20b92,889 crore EBITDA: \u20b91,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Torrent Pharmaceuticals Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171800,"url":"https:\/\/alphastreet.com\/india\/vakrangee-q2-fy26-earnings-results\/","url_meta":{"origin":172484,"position":2},"title":"Vakrangee Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"October 24, 2025","format":false,"excerpt":"Incorporated in 1990, Vakrangee Ltd provides diverse solutions, and activities in the e-commerce sector, including bullion and jewellery, through its Vakrangee Kendra (on B2B and B2C basis), and handles multi-state data digitization, software, and licence. Presenting below are its Q2 FY26 earnings results. \u00a0 Q2 FY26 Earnings Results Revenue from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Vakrangee Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Vakrangee-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Vakrangee-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Vakrangee-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Vakrangee-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Vakrangee-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Vakrangee-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172613,"url":"https:\/\/alphastreet.com\/india\/v-mart-q2-fy26-earnings-results\/","url_meta":{"origin":172484,"position":3},"title":"V Mart Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 20, 2025","format":false,"excerpt":"V-Mart Retail is engaged in the business of Value Retailing through the chain of stores situated at various cities in India. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b9806.9 crore, up 22.0% YoY from \u20b9660.9 crore in Q2 FY25, though down sequentially from \u20b9885.2 crore in Q1 FY26.\u200b Total\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"V Mart Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/V-Mart-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/V-Mart-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/V-Mart-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/V-Mart-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/V-Mart-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/V-Mart-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":173202,"url":"https:\/\/alphastreet.com\/india\/rossari-biotech-q3-fy26-earnings-results\/","url_meta":{"origin":172484,"position":4},"title":"Rossari Biotech Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 20, 2026","format":false,"excerpt":"Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. Their 3 main product categories are:- Home, personal care, and performance chemicals- Textile specialty chemical- Animal health and nutrition The company has two R&D facilities, one at Silvassa manufacturing facility and a\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Rossari Biotech Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rossari-Biotech-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rossari-Biotech-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rossari-Biotech-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rossari-Biotech-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rossari-Biotech-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rossari-Biotech-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":173194,"url":"https:\/\/alphastreet.com\/india\/tips-music-q3-fy26-earnings-results\/","url_meta":{"origin":172484,"position":5},"title":"Tips Music Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 20, 2026","format":false,"excerpt":"Tips Industries Limited, incorporated in 1996, is engaged in the business of Production and Distribution of motion Pictures and acquisition and exploitation of Music of Rights. The company is also a leading producer of Punjabi films in the country. Q3 FY26 Earnings Results Revenue from Operations: \u20b994.3 crore, up 6.0%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Tips Music Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Tips-Music-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Tips-Music-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Tips-Music-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Tips-Music-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Tips-Music-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Tips-Music-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172484"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172484\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172485"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}